----item----
version: 1
id: {02E281E3-2AEB-4614-A102-1BBD199B1D02}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/03/20/Ariad shareholder class action dismissed
parent: {AD42DA69-3D39-4357-AFF7-F14E275A07AC}
name: Ariad shareholder class action dismissed
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 9a4f7c89-5281-4021-8b63-6519ce578023

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 77

{6DDF7877-FDAE-472B-8739-FB4710DF7651}|{728904A1-7259-48E8-8256-60D002A0BFEA}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 40

Ariad shareholder class action dismissed
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 40

Ariad shareholder class action dismissed
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 2352

<p>Investors' enthusiasm over a district court dismissing a shareholder class action suit against Ariad Pharmaceuticals was short-lived on 25 March, with shares climbing only 25 cents, or about 3%, before falling 29 cents, or about 3.5%, to close at $8.09.</p><p>The suit was filed in late 2013 in connection with the events leading up to the FDA's requested <a href="http://www.scripintelligence.com/home/Ariad-suspends-Iclusig-sales-temporarily-on-FDA-concerns-shares-plummet-347774" target="_new">temporary suspension</a> of the marketing and commercial distribution of Iclusig (ponatinib) on 31 October 2013, based on reports of serious and life-threatening blood clots and severe narrowing of blood arteries and veins in patients taking the medicine, and the subsequent <a href="http://www.scripintelligence.com/business/Iclusig-back-on-US-market-Ariad-rises-349430" target="_new">re-launch</a> of the kinase inhibitor in January 2014 based on <a href="http://www.scripintelligence.com/home/Ariad-leukemia-drug-Iclusig-makes-swift-US-return-but-under-restrictions-348963" target="_new">revised US prescribing</a> information and risk evaluation and mitigation strategy plan.</p><p>The suit alleged certain company officials made a series of false and misleading statements about the safety, efficacy and commercial prospects of Iclusig, which is approved in the US to treat chronic myeloid leukemia or Philadelphia-chromosome positive acute lymphoblastic leukemia. </p><p>The court granted Ariad's motion to dismiss the lawsuit &ndash; concluding the plaintiffs failed to establish that any such statements violated the firm's disclosure obligations as asserted in the complaint.</p><p><b>Related articles:</b></p><p><a href="http://www.scripintelligence.com/home/Ariad-suspends-Iclusig-sales-temporarily-on-FDA-concerns-shares-plummet-347774" target="_new">Ariad suspends Iclusig sales 'temporarily' on FDA concerns; shares plummet</a></p><p><a href="http://www.scripintelligence.com/home/Ariad-leukemia-drug-Iclusig-makes-swift-US-return-but-under-restrictions-348963" target="_new">Ariad leukemia drug Iclusig makes swift US return, but under restrictions</a></p><p><a href="http://www.scripintelligence.com/business/Iclusig-back-on-US-market-Ariad-rises-349430" target="_new">Iclusig back on US market; Ariad rises</a></p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 260

<p>Investors' enthusiasm over a district court dismissing a shareholder class action suit against Ariad Pharmaceuticals was short-lived on 25 March, with shares climbing only 25 cents, or about 3%, before falling 29 cents, or about 3.5%, to close at $8.09.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 40

Ariad shareholder class action dismissed
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150320T140000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150320T140000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150320T140000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028237
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 40

Ariad shareholder class action dismissed
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 6

People
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357408
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042321Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

9a4f7c89-5281-4021-8b63-6519ce578023
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042321Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
